TMOD2 high expression levels correlate with high survival probability and favorable disease outcome in neuroblastoma patients’ [25], while TMOD3 up regulation is responsible for chemotherapeutic agents’ resistance in non-small cell lung carcinoma [26]. This evidence concerns the gene TMOD2 and neuroblastoma.